Recommended

Discover how to overcome low affinity or poor TCR yields that are slowing you down in this upcoming webinar – register your details today
WEBINAR | Discover how advances can expand the possibilities for drug discovery, from target validation to preclinical development
Facing roadblocks in obesity drug discovery? Discover how integrated, validated strategies are helping teams accelerate development and reduce risk – register your details now
Unlock the science, strategy and real-world impact behind the next generation of precision therapies – access our new brand report now >>
Safety data is no longer just a regulatory checkbox – it’s a strategic advantage. Find out more in our upcoming webinar, register your details today
Explore how AI is reshaping early drug discovery, from target identification and compound screening to predictive modelling and trial design – register now!
news

University at Buffalo to develop drugs that stop ovarian cancer from feeding on fat

The University at Buffalo has received a $2.3 million grant from the US National Cancer Institute to identify metabolic vulnerabilities of ovarian cancer and to develop potential treatments for the disease.

3D illustration of ovarian cancer

The University at Buffalo School of Pharmacy and Pharmaceutical Sciences, US has recently received a $2.3 million grant from the US National Cancer Institute to fast-track the development of drugs that target apelin, a peptide that when expressed within body fat helps ovarian cancer cells better consume lipids, and the apelin receptor (APJ). The researchers will use a combined experimental and computational mathematical modelling approach to identify metabolic vulnerabilities of ovarian cancer and to develop potential treatments for the disease.

High-grade serous ovarian cancer is the most common and malignant form of ovarian cancer. Its high mortality rate is largely due to most patients being diagnosed with advanced-stage disease when tumours are widely metastasised and have developed drug resistance. 

Unlike most other cancers, ovarian cancer cells primarily metastasise within the abdomen, preferably in lipid-rich areas such as the omentum. Ovarian cancer cells rely on lipids as an energy source for survival, spread and drug resistance.

 

Reserve your FREE place

 


AI-powered drug discovery: Accelerating the development of life-saving therapies

18 September 2025 | 14:00PM BST | FREE Webinar

Join this webinar to learn how AI is accelerating early-stage drug discovery and improving target identification, practical strategies for applying AI effectively within your organisation and to ask your questions to our industry expert! Dr Remco Jan Geukes Foppen will share practical insights into how AI is being applied across the pharmaceutical sector, helping teams move faster and make better-informed decisions. With experience spanning data management, image analysis, bioinformatics, and machine learning in clinical research, he brings both deep technical expertise and strategic understanding of real-world challenges.

Register Now – It’s Free!

 

“By completing these studies, we will establish the importance of apelin and APJ as a therapeutic target in ovarian cancer – a malignancy for which effective therapies are desperately needed to improve patient outcomes,” said Dr Sukyung Woo, research lead.

The investigators will also explore the significance of ovarian cancer cells’ capacity to form cell clusters called spheroids, which travel through bodily fluids to reach new sites within the abdomen. 

APJ promotes the spread and chemoresistance of ovarian cancer cells by regulating their capacity to form spheroids and their metabolic switch to using lipids as energy, and by supporting the formation of new blood vessels through a process called angiogenesis. 

Previous studies led by the researchers have found that greater expression of apelin and APJ within tumour microenvironments resulted in increased use of lipids as energy by ovarian cancer cells, leading to better survival, fitness and spread of the cells.